Moximed develops innovative therapies for patients with knee osteoarthritis.
Moximed has raised $61.0M in total funding. The most recent round was Series D. The last funding was announced in August 2024.
Moximed's investors include New Enterprise Associates, Vertex Ventures, Cormorant Asset Management, Frazier Healthcare Partners, Vertex Ventures HC.
Moximed is headquartered in Hayward, United States.
Moximed develops innovative therapies for patients with knee osteoarthritis.
Moximed is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Moximed — Funding & Investors." VCBacked, August 13, 2024, https://www.vcbacked.co/company/moximed. Accessed October 16, 2026.
VCBacked. (2024). Moximed — Funding & Investors. Retrieved October 16, 2026, from https://www.vcbacked.co/company/moximed
{{cite web |title=Moximed — Funding & Investors |url=https://www.vcbacked.co/company/moximed |website=VCBacked |access-date=October 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated